Statements (20)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2021
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
M09AX10
|
| gptkbp:brand |
casimersen
|
| gptkbp:CASNumber |
1804097-07-1
|
| gptkbp:chemicalFormula |
C615H955N177O176P30
|
| gptkbp:form |
solution for injection
|
| https://www.w3.org/2000/01/rdf-schema#label |
Amondys 45
|
| gptkbp:indication |
gptkb:Duchenne_muscular_dystrophy
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Sarepta_Therapeutics
|
| gptkbp:mechanismOfAction |
exon 45 skipping
|
| gptkbp:pregnancyCategory |
N
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:synonym |
casimersen
|
| gptkbp:targetAudience |
patients with DMD amenable to exon 45 skipping
|
| gptkbp:UNII |
6QY1D9Y4F1
|
| gptkbp:bfsParent |
gptkb:Sarepta_Therapeutics
|
| gptkbp:bfsLayer |
7
|